Product Manager
Todd Giardiello holds a Bachelor of Science in Microbiology from Kutztown University and has been a part of the Rockland team since 2008. Over the years, he has progressed through several key positions in our manufacturing departments, now excelling as a Product Manager. Todd combines a strong scientific background with practical management skills to drive projects forward effectively. Away from work, he enjoys engaging in sports and the creative hobby of Lego construction, showcasing a well-rounded blend of interests.
Articles
-
Evaluation of Novel High-Coverage Generic CHO-HCP Reagents
Here we evaluate and demonstrate improved coverage of a new generic CHO-HCP reagent developed at Rockland. -
Localization and Quantification of Oligonucleotide Therapeutic Drugs
This poster presents the development of universal detection reagents specific for nucleic acid modifications. -
Lyme Disease: The Situation & Solution
Our solution engages the evasive nature of B. burgdorferi and the different bacterial phases and allows for the detection of the unique response of each patient. -
New Tools to Quantify and Localize ASOs and siRNAs
This white paper introduces ModDetect™ antibody panels, new tools for detecting and localizing modified antisense oligonucleotides (ASOs) and siRNAs. Traditional methods like qPCR fall short with modified ONTs, while ModDetect™ provides a sensitive, versatile solution for assays such as ELISA and immunofluorescence, supporting ONT biodistribution and therapeutic studies. -
Robust Methods for Anti-Oligonucleotide Antibody Generation
In this poster we summarize our expertise in developing oligo-specific antibody reagents to a number of different target chemistries. -
The Utility of Antibodies When Investigating SARS-CoV-2 & Variants of Concern
This white paper discusses the drawbacks of monoclonal antibodies and the benefits of polyclonal antibodies in infectious disease detection. Plus, we show the detection of the Omicron variant by immunofluorescence microscopy within infected A549 cells using Rockland's polyclonal anti-Nucleocapsid antibody.